Tenosynovial giant cell tumors as accidental findings after episodes of distortion of the ankle: two case reports

<p>Abstract</p> <p>Introduction</p> <p>Tenosynovial giant cell tumors are benign tumors of uncertain pathogenesis. They occur in the joints, tendons and synovial bursas. Due to a high recurrence rate of up to 50%, some authors call a giant cell tumor a semimalignant tumor. To date, less than 10 cases of tenosynovial giant cell tumor of the ankle have been published in the international medical literature.</p> <p>Case presentation</p> <p>In this case report, we present two patients with localized tumors that were detected accidentally after the occurrence of ankle sprains with persisting pain in the joint. The tumors were resected by open marginal surgery and regular follow-up examinations were carried out.</p> <p>Conclusions</p> <p>We present an unusual occurrence of a tumor along with a possible follow-up strategy, which has not been previously discussed in the international literature.</p

Suture anchors, properties versus material and design: A biomechanical study in ovine model

The aim of our work was to compare the performance of suture anchors with various material and design that could be used in shoulder surgery. Three metallic and three bioabsorbable anchors mounted with stainless steel wire were tested. Their load to failure and mode of failure was determined in ex vivo ovine glenoids using Materials Testing Machine and attached load cell. Tensile load was applied at a rate of 60 mm/min, while load and displacement were recorded at a sampling rate of 100 Hz. Load to failure and failure mode was recorded. The mean load to failure for screw-type metallic anchors was Arthrex Fastak 678.3 N and Smith+Nephew Ti 3.5 499.7 N. Mitek GII (cylindrical with arcs) had a load to failure of 86.8 N. All bioabsorbable anchors exhibited lower load to failure comparing to screw-type metallic ones (P = 0.007), which was not statistically different between each other (P = 0.056): Arthrex BioFastak: 179.5 N; Mitek Panalok: 136.0 N; Smith+Nephew Bioraptor: 258.8 N. Metallic or bioabsorbable anchors had 30% eyelet failure (5/15 and 4/13, respectively). Our results suggest that metallic anchors have a better load to failure than bioabsorbable ones. Often the suture anchors&apos; weak point is their eyelet and needs further design improvement. © 2010 Springer-Verlag

A radiological and laboratory assessment of polyethylene wear in failed total hip replacement

This study assessed the reliability of radiological assessment of polyethylene wear in loose total hip replacements (THRs) by comparing it with a laboratory assessment using the shadowgraph technique. It was performed in Avon Orthopaedic Centre, Southmead Hospital, from September 1997 to June 1998. True linear wear depth measured using the shadowgraph technique was 42% greater than that determined from the radiological femoral head eccentricity in standard non-weightbearing plain x-rays. There was an inverse statistically significant correlation between cup inclination angle and the volumetric wear rate. The linear wear rate, as determined with the shadowgraph technique, was greater in retrieved cups during the first six years postoperatively, but reduced to a lower level in cups retrieved after that time of service.</jats:p

No Effect of Rosuvastatin in the Zoledronate-Induced Acute-Phase Response

Endocrinolog

Changes of circulating MicroRNAs in response to treatment with teriparatide or denosumab in postmenopausal osteoporosis

Context: Expression of microRNAs (miRs) related to bone metabolism in the serum may be affected by antiosteoporotic treatment. Objective: To investigate the effect of two antiosteoporotic agents with opposite effects on bone metabolism on miR expression profile in the serum. Design: Observational, open label, nonrandomized clinical trial. Setting: The outpatient clinics for Metabolic Bone Diseases of 424 General Military Hospital, Thessaloniki, Greece. Patients and Interventions: Postmenopausal women with low bone mass were treated with either teriparatide (TPTD; n = 30) or denosumab (n = 30) for 12 months. Main Outcome Measures: Changes in the serum expression of selected miRs linked to bone metabolism at 3 and 12 months of treatment. Secondary measurements: associations of measured miRs with changes in bone mineral density (BMD) at 12 months and the bone turnover markers (BTMs) C-terminal cross-linking telopeptide of type I collagen and procollagen type I N-terminal propeptide at 3 and 12 months. Results: We found significantly decreased relative expression of miR-33-3p at 3 months (P = 0.03) and of miR-133a at 12 months (P = 0.042) of TPTD treatment. BMD values at 12 months of TPTD treatment were significantly and inversely correlated with miR-124-3p expression at 3 months (P = 0.008). Relative expression of miR-24-3p and miR-27a was correlated with changes in BTMs during TPTD treatment and of miR-21-5p, miR-23a-3p, miR-26a-5p, miR-27a, miR-222-5p, and miR-335-5p with changes in BTMs during denosumab treatment. Conclusions: Circulating miRs are differentially affected by treatment with TPTD and denosumab. TPTD affects the relative expression of miRs related to the expression of RUNX-2 (miR-33) and DKK-1 gene (miR-133). Copyright © 2018 Endocrine Society

Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass

Bone and mineral researc